Attentive Science is proud to welcome Dr. Basel Assaf, BVSc, PhD, DACVP, DABT, FIATP as our new Vice President of Toxicology and Pathology.
This appointment underscores our commitment to bringing the best of the best to our A team and to our clients worldwide. Dr. Assaf brings an exceptional educational background and extensive experience from leading pharmaceutical companies, including his most recent roles at Sanofi and Pfizer. Coming from large biopharma, he gives Attentive an enhanced perspective on our clients’ needs, ensuring that our services are closely aligned with the challenges and expectations they face.
At Attentive Science, we are dedicated to helping our clients bring medicines from concept to clinic efficiently and responsibly. We value sound science, the wise use of resources, and a steadfast commitment to excellence.
Dr. Assaf is a recognized thought leader in cell and gene therapy preclinical development. He frequently speaks at international scientific meetings, engages with the U.S. FDA, and serves as a key resource for peers across the industry on the cell and gene therapy drug development process. Beyond cell and gene therapies, he also brings a broad range of experience across different drug modalities.
Together with our global presence and expert teams in Kansas (USA), Australia, and Abu Dhabi (UAE), Attentive Science offers a truly solution-oriented approach to supporting our sponsors’ therapies.
Please join us in welcoming Dr. Assaf to Attentive Science!